Post-operative pain control in patients on buprenorphine or methadone for opioid use disorder

Aurora Quaye; Tal Tsafnat; Janelle M. Richard; Henry Stoddard; David J. Gagnon

doi:10.5055/jom.0823

Authors

Aurora Quaye, MD https://orcid.org/0000-0002-7573-2164
Tal Tsafnat, BA, MS
Janelle M. Richard, BA https://orcid.org/0000-0002-2825-6134
Henry Stoddard, MPH
David J. Gagnon, PharmD

DOI:

https://doi.org/10.5055/jom.0823

Keywords:

methadone, buprenorphine, pain, post-operative, opioid-related disorders, analgesics, opioid

Abstract

Objective: This study aimed to determine whether there is a difference in pain scores and opioid consumption after elective surgery in patients maintained on methadone or buprenorphine for opioid use disorder (OUD). Additionally, we investigated the impact of continuing or discontinuing methadone or buprenorphine on post-operative pain outcomes.

Design: A single-center retrospective cohort study.

Setting: Tertiary care medical center.

Patients and participants: Adults aged 18 years or older with OUD maintained on buprenorphine or methadone who underwent elective surgery between January 1, 2017, and January 1, 2021.

Interventions: Patients were identified through electronic medical records, and demographic and clinical data were collected.

Main outcome measures: The primary outcome was opioid consumption at 24 hours post-operatively, measured in milligram morphine equivalents. The secondary outcome was opioid consumption and pain scores up to 72 hours postoperatively, assessed using a numeric rating scale.

Results: This study included 366 patients (64 percent on buprenorphine and 36 percent on methadone). Opioid utilization significantly increased when buprenorphine was not administered post-operatively. Both groups exhibited comparable total opioid consumption during the post-operative period. In the buprenorphine cohort, pain scores differed significantly based on the receipt of medications for OUD post-operatively.

Conclusions: This study reinforces existing evidence supporting the continuation of medications for opioid use disorder, specifically buprenorphine and methadone, during the perioperative period. Dissemination of guideline recommendations is essential to ensure optimal post-operative pain management for this patient population.

Author Biographies

Aurora Quaye, MD

Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland; Division of Anesthesiology, Spectrum Healthcare Partners, South Portland, Maine; Tufts University School of Medicine, Boston, Massachusetts

Tal Tsafnat, BA, MS

University of New England College of Osteopathic Medicine, Portland, Maine

Janelle M. Richard, BA

Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, Maine

Henry Stoddard, MPH

Center for Interdisciplinary Population & Health Research, Maine Health Institute for Research, Scarborough, Maine

David J. Gagnon, PharmD

Tufts University School of Medicine, Boston, Massachusetts; Department of Pharmacy, Maine Medical Center, Portland; MaineHealth Institute for Research, Scarborough, Maine

References

Alderks CE: Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update). The CBHSQ Report: August 22, 2017. Substance Abuse and Mental Health Services Administration (US), 2017.

Schuler MS, Saloner B, Gordon AJ, et al.: National trends in buprenorphine treatment for opioid use disorder from 2007 to 2018. Subst Abus. 2023; 44: 154-163.

Biondi BE, Vander Wyk B, Schlossberg EF, et al.: Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addict Sci Clin Pract. 2022; 17(1): 15.

Hser YI, Evans E, Huang D, et al.: Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016; 111(4): 695-705.

Mattick RP, Breen C, Kimber J, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014; 2014(2): Cd002207.

Smith K, Wang M, Abdukalikov R, et al.: Pain management considerations in patients with opioid use disorder requiring critical care. J Clin Pharma. 2022; 62(4): 449-462.

Gudin J, Fudin J: A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain Ther. 2020; 9(1): 41-54.

Substance Abuse and Mental Health Services Administration: Medications for opioid use disorder. Available at https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf. Accessed August 22, 2023.

Ward EN, Quaye AN, Wilens TE: Opioid use disorders: Perioperative management of a special population. Anesth Analg. 2018; 127(2): 539-547.

Coluzzi F, Bifulco F, Cuomo A, et al.: The challenge of perioperative pain management in opioid-tolerant patients. Ther Clin Risk Manag. 2017; 13: 1163-1173.

Sritapan Y, Clifford S, Bautista A: Perioperative management of patients on buprenorphine and methadone: A narrative review. Balkan Med J. 2020; 37(5): 247-252.

Anderson TA, Quaye ANA, Ward EN, et al.: To stop or not, that is the question: Acute pain management for the patient on chronic buprenorphine. Anesthesiology. 2017; 126(6): 1180-1186.

Jonan AB, Kaye AD, Urman RD: Buprenorphine formulations: Clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures. Pain Phys. 2018; 1(1): E1-E12.

Kohan L, Potru S, Barreveld AM, et al.: Buprenorphine management in the perioperative period: Educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021; 46(10): 840-859.

Quaye AN, Zhang Y: Perioperative management of buprenorphine: Solving the conundrum. Pain Med. 2019; 20(7): 1395-1408.

Selvamani BJ, Kral L, Swaran Singh T: Perioperative management of patients on buprenorphine for opioid use disorder. ASRA Pain Medicine News. 2022; 47: 10. DOI: 10.52211/asra020123.010.

Quaye A, Mardmomen N, Mogren G, et al.: Current state of perioperative buprenorphine management—A national provider survey. J Addict Med. 2023; 17: 640-645. DOI: 10.1097/ADM.0000000000001191.

Macintyre PE, Russell RA, Usher KA, et al.: Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care. 2013; 41(2): 222-230.

Quaye A, Potter K, Roth S, et al.: Perioperative continuation of buprenorphine at low-moderate doses was associated with lower post-operative pain scores and decreased outpatient opioid dispensing compared with buprenorphine discontinuation. Pain Med. 2020; 21(9): 1955-1960.

Schuster B, Bell B, Massoll A, et al.: Continuation versus discontinuation of buprenorphine in the perioperative setting: A retrospective study. Cureus. 2022; 14(3): e23385.

Wyse JJ, Herreid-O'Neill A, Dougherty J, et al.: Perioperative management of buprenorphine/naloxone in a large, national health care system: A retrospective cohort study. J Gen Intern Med. 2022; 37(12): 2998-3004.

Gerbershagen HJ, Aduckathil S, van Wijck AJ, et al.: Pain intensity on the first day after surgery: A prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013; 118(4): 934-944.

Centers for Disease Control and Prevention: CDC clinical practice guideline for prescribing opioids for pain. Available at https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm#T1_down. Accessed August 22, 2023.

McPherson MLM: Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, 2019.

Ostelo RW, Deyo RA, Stratford P, et al.: Interpreting change scores for pain and functional status in low back pain: Towards international consensus regarding minimal important change. Spine (Phila Pa 1976). 2008; 33(1): 90-94.

Larochelle MR, Bernson D, Land T, et al.: Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018; 169(3): 137-145.

Moreno JL, Wakeman SE, Duprey MS, et al.: Predictors for 30-day and 90-day hospital readmission among patients with opioid use disorder. J Addict Med. 2019; 13(4): 306-313.

Wakeman SE, Larochelle MR, Ameli O, et al.: Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020; 3(2): e1920622.

Dale RC, Metcalf CL, Bockman C, et al.: Comparison of PACU length of stay and opioid requirements of patients maintained on buprenorphine or methadone for opioid use disorder. J Opioid Manag. 2022; 18(1): 7-15.

Vilkins AL, Bagley SM, Hahn KA, et al.: Comparison of post-cesarean section opioid analgesic requirements in women with opioid use disorder treated with methadone or buprenorphine. J Addict Med. 2017; 11(5): 397-401.

Komatsu R, Nash M, Peperzak KA, et al.: Comparison between preoperative methadone and buprenorphine use on post-operative opioid requirement: A retrospective cohort study. Clin J Pain. 2022; 38(5): 311-319.